NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
21/02/2026
Voltar para busca
Dado oficial do USPTO
OBI PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
17/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
18/07/2013
Data de registro
19/05/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/02/2026
Última transação
17/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
3
Tipo de titular
03
Localização do titular
Taipei City, TW
Examinador
WIENER, MICHAEL
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the letters "OBI", with the letter "O" in teal and light teal and in the form of a spinning wheel, with the letters "BI" in teal. Beneath these letters is a curved line in teal. Beneath the curved line is the term "PHARMA" in teal.
Titulares e representantes
Titulares
OBI PHARMA, INC.
OBI PHARMA, INC.
Representantes
Michael T. Smith Birch, Stewart, Kolasch & Birch, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Antibiotic preparations; Antibiotics; Anti-cancer preparations; Anti-infectives; Anti-inflammatories; Biological preparations for the treatment of cancer; Chemical reagents for medical or veterinary purposes; Diagnostic agentspreparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodiesbuffers and reagents for use in disease testing; Diagnostic preparations for medical and veterinary use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic preparations for medical purposes; Diagnostic radiopharmaceutical preparations; Diagnostic reagents for medical use; Diagnostic reagents and contrast media for medical use; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Gastro-intestinal treatment preparations; In-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; Medical diagnostic reagents and assays for testing body fluids; Medical diagnostic reagents and assays for testing body fluids for microorganisms; Medical diagnostic reagents for the analysis of body fluids; Medicinal preparations for the treatment of infectious diseases and for using in oncology; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti - infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Reagents and media for medical and veterinary diagnostic purposes; Reagents for medical use; Vaccine adjuvants; Vaccine preparations; Vaccine stabilizers; Vaccines
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
21/02/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
21/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/02/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
19/11/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
19/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/03/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
27/03/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/03/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/03/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/03/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/03/2024
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
02/04/2022
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
02/04/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/04/2022
ES8R
TEAS SECTION 8 RECEIVED
24/09/2021
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
19/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/05/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
19/05/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2015
PUBO
PUBLISHED FOR OPPOSITION
03/03/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/02/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/01/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/01/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/01/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/01/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/01/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/07/2014
GNRT
NON-FINAL ACTION E-MAILED
16/07/2014
CNRT
NON-FINAL ACTION WRITTEN
16/07/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2014
ALIE
ASSIGNED TO LIE
04/07/2014
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/06/2014
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
21/03/2014
GNSL
LETTER OF SUSPENSION E-MAILED
21/03/2014
CNSL
SUSPENSION LETTER WRITTEN
21/03/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/03/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/03/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/03/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/11/2013
GNRT
NON-FINAL ACTION E-MAILED
06/11/2013
CNRT
NON-FINAL ACTION WRITTEN
06/11/2013
DOCK
ASSIGNED TO EXAMINER
31/10/2013
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
07/08/2013
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/08/2013
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
06/08/2013
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
25/07/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/07/2013
NWAP
NEW APPLICATION ENTERED
22/07/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OBI PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.